Upload File

alnylam® pharmaceuticals...michael polydefkisl, angela dispenzieri2 ijohns hopkins, baltimore, md,...

  • Home
  • Documents
  • Alnylam® Pharmaceuticals...Michael Polydefkisl, Angela Dispenzieri2 IJohns Hopkins, Baltimore, MD, USA; 2Mayo Clinic, Rochester, MN, ... Further analysis by baseline risk factors
1

Upload: others

Post on 07-Aug-2020

0 views

Category:

Documents


0 download

Report

TRANSCRIPT

Page 1: Alnylam® Pharmaceuticals...Michael Polydefkisl, Angela Dispenzieri2 IJohns Hopkins, Baltimore, MD, USA; 2Mayo Clinic, Rochester, MN, ... Further analysis by baseline risk factors

Alnylam 2015 PowerPoint

APPRAISAL OF ROCHESTER STATE HOSPITAL Rochester

Advances in RNAi Therapeutics Platform · 2019-12-14 · 3 Founded on the Bold Promise of Turning Nobel Prize Winning Science into a New Class of Medicine Alnylam Pharmaceuticals

Path to Alnylam 2020 · Path to Alnylam 2020 R&D Day 2015 John Maraganore, Ph.D., Chief Executive Officer . 2 What we’re about: RNAi Therapeutics •Harness natural pathway

Corporate Overview (JPM) - Alnylam Pharmaceuticals · Alnylam Forward Looking Statements . This presentation contains forward-looking statements. There are a number of important factors

Anita - Alnylam® Pharmaceuticals · • Concomitant quantitative bone marrow failure in ~50% of patients with anemia and ... and inflammation causes C5 fluctuations of up to ~100%1

Alnylam 2015 PowerPoint - Jefferies Pharma.pdf · 2 Alnylam Forward Looking Statements ... PBO: 7.4 ± 6.9 . Drug: 2.3 ± 6.0 ... Co-inheritance of thrombophilic traits in hemophilia

Corporate Overview - Alnylam Pharmaceuticals › web › assets › ALNY-CorpDeck-PRES-Sept… · Corporate Overview . Alnylam Forward Looking Statements 2 This presentation contains

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW … · by and regarding Alnylam Pharmaceuticals, Inc. (“ Alnylam” or the “Company”), analysts’ reports and advisories

SPECIAL NEWS ITEM - PBL Technology · Alnylam Pharmaceuticals, Inc. Plant Bioscience Limited here P B L N e w s-I s s u e 2 3-M a y 2 0 1 2 ... Alnylam and Isis co-founded Regulus

Report 2017 Alnylam Pharmaceuticals, Inc. Annual · Alnylam Pharmaceuticals, Inc. Annual Report 2017 Form 10-K (NASDAQ:ALNY) Published: February 15th, 2017 PDF generated by stocklight.com

Harnessing RNAi · Harnessing RNAi: Alnylam Pharmaceuticals is conquering rare diseases one drug at a time BUILDING A CANADIAN PRESENCE AND BEYOND “Having the opportunity to work

New Co-Ops & Summer Internships - Alnylam Pharmaceuticals · 2020. 10. 5. · contractor after my co-op ended, and I continue to learn and grow every day I’m here.” Victoria Guan,

impact - Aplastic Anemia & MDS International Foundation · • Achillion Pharmaceuticals, Inc. • Actinium Pharmaceuticals, Inc. • Agios Pharmaceuticals • Akari Pharmaceuticals

Takeda Pharmaceuticals v. Amneal Pharmaceuticals

16-Sep-2019 Alnylam Pharmaceuticals, Inc. · 2020. 8. 3. · Since there are other sponsored genetic testing programs available and HCPs are also able to use their own reimbursed

Pharmaceuticals and Bio Pharmaceuticals

2020 Alnylam Rare Disease Trend Report...7 PERSPECTIVES FROM HEALTHCARE PAYERS 2020 Alnylam Rare Disease Trend Report Rare diseases are defined by the U.S. Food & Drug Administration

MCC Students Succeed · PDF fileAzab, Yehia Rochester Aziz, Dilan Rochester Baackes, Margaret Rochester Babb, Elizabeth Rochester Bahai, Melle Rochester Bailey, Kyle Rochester Bailey,

Rochester Public Utilities Rochester, Minnesota

Alnylam Pharmaceuticals Presentation FD

ESC+ design minimizes the off-target potential and further ... · 10/1/2018  · Alnylam Pharmaceuticals ESC+ design minimizes the off-target potential and further ... results, performance

Research Initiation Many Shots on Goal Highlights · 2017. 3. 3. · ALN-TTR02 TTR amyloidosis (FAP) phase 3 Alnylam Pharmaceuticals phase 3 results (2016-2017) TKM-Ebola Ebola phase

ALN-VSP02 Phase 1 Trial Update - Alnylam Pharmaceuticals · Liver Targeting In Vivo Silencing of ApoB in Non-Human Primates 4 Nature, 441, 111-114, Mar 2006 0 20 40 60 80 100 1mg/kg

Alnylam Pharmaceuticals · 12 Patisiran Interim Phase 2 OLE Study Results* Ongoing Study in FAP Patients PLANNED NEXT STEPS 24-month Phase 2 OLE data • in mid-2016 *Preliminary

Corporate Overview - Alnylam Pharmaceuticals · Alnylam Forward Looking Statements 2 This presentation contains forward-looking statements, within the meaning of Section 27A of the

210922Orig1s000 - Food and Drug Administration · Alnylam Pharmaceuticals Inc. (Alnylam) submitted a New Drug Application ... of the FD&C Act: FDAAA factor (F): ... The clinical presentation

Alnylam Pharmaceuticals Inc RNAi Roundtable: ALN · PDF fileTHOMSON REUTERS STREETEVENTS EDITED TRANSCRIPT ALNY - Alnylam Pharmaceuticals Inc RNAi Roundtable: ALN-AT3 for the treatment

THE ROLE OF PHARMACEUTICALS IN PUBLIC HEALTH · Vin Sharma, Senior Director of Business Planning and Program/ Alliance Management at Alnylam Pharmaceuticals, Boston, MA noon – 1

RNAi Roundtable - Alnylam Pharmaceuticals...July 22, 2014 RNAi Roundtable: Advances in Delivery of RNAi Therapeutics with Enhanced Stabilization Chemistry (ESC)-GalNAc-siRNA Conjugates

Fearless in Pharma AGENDA - Momentum Events · 2021. 6. 27. · Sara Nochur Chief Diversity, Equity and Inclusion Officer ALNYLAM PHARMACEUTICALS Deborah Dunsire, M.D. Chief Executive

PowerPoint - 4x3 Arial - Alnylam® Pharmaceuticals Algorithm, Abbvie, Resverlogix, Cerenis Disclosures. 3 Background LDL-C variability common, associated with worse outcomes . …

Investigation of Mortality Imbalance in ... - Alnylam DE...revusiran Phase 2 Open Label Extension study (OLE), Alnylam requested ad-hoc ENDEAVOUR Data Monitoring Committee (DMC) meeting

Co-Ops & Summer Internships - Alnylam Pharmaceuticals · 2020-04-07 · RNAi was first discovered in the purple petunia flower and later translated into worms by biologists Andrew

Delivery Roundtable draft 7.ppt - Alnylam Pharmaceuticals · Jejunum 140 e nt group Liver Jejunum 100 Saline treatm 120 60 80 e nt relative to * * * 20 40 B mRNA cont * 0 saline Chol-luc-